A Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to test the beneficial effect of a pharmacist-initiated knowledge transfer intervention to both patients and prescribers on the discontinuation of inappropriate prescriptions, compared to usual care. The investigators hypothesize that the pharmacist-led intervention will reduce inappropriate prescriptions by at least 20% over 6-months compared to usual care. The intervention consists of simultaneously educating consumers and providing physicians with an evidence-based pharmaceutical opinion on inappropriate prescriptions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deprescribing in Primary Health Care

NCT03903484

Inappropriate Prescribing Primary Health Care Polypharmacy

COMPLETED NA

Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents

NCT03655405

Polypharmacy Inappropriate Prescribing

COMPLETED NA

Deprescribing Intervention Among Nursing Home Residents With Major Neurocognitive Disorders

NCT05155748

Dementia

COMPLETED NA

Trial of a Pharmacist-physician Intervention Model to Reduce High-risk Drug Use by Hospitalised Elderly Patients

NCT02570945

Potentially Inappropriate Medication Use

COMPLETED PHASE4

Effects of Communication Training to Involve Older People in Decisions to DEPRESCRIBE Cardiometabolic Medication: a Cluster-randomized Trial in Primary Care

NCT05507177

Deprescriptions Polypharmacy Primary Health Care +2 more

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inappropriate Dose of Drug Administered Health Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacist-led educational intervention

Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.

Group Type EXPERIMENTAL

Pharmacist-led educational intervention

Intervention Type BEHAVIORAL

1\) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.

Control

Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist-led educational intervention

1\) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women 65 years of age and older (no upper age limit)
* Individuals for whom prescription claims derive from only one pharmacy identifier
* Chronic consumption (\> 3 month claims) of one of the target inappropriate prescriptions. (benzodiazepine/non benzodiazepine hypnotic, long-acting sulfonylurea oral hypoglycemic agents, anticholinergic agents (in the form of first-generation antihistamines) or Nonsteroidal anti-inflammatory drugs \[NSAIDs\] )
* Patients who are willing to participate in the study.

Exclusion Criteria

* A probable diagnosis of dementia (persons without the capacity to provide informed consent), as determined by a) a prescription for memantine or a cholinesterase inhibitor; b) report from a caregiver or family-member; or c) a baseline screening score on the Folstein Mini-Mental State Exam \< 24
* Inability to understand and or communicate in English and/or French
* Patients living in a long-term care facility
* Concomitant use of any antipsychotic medication

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No